Pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly

PurposeAcromegaly may be associated with an increased risk of complex intraoperative management and anesthetic complications. No study addressed whether pretreatment with somatostatin receptor ligands (SRLs) affects anesthesiologic management.MethodsWe studied 211 consecutive acromegalic patients who had a recorded intraoperative computerized anesthetic record (ICAR) available for analysis. Ninety-six (45.5%) patients were SRL-pretreated while 115 patients were treatment naive.ResultsTreatment with SRLs reduced mean basal growth hormone level from 23.84.2 to 5.9 +/- 1.3 mu g/L. Normalization of insulin-like growth factor-1 was achieved in 26 patients (27.1%). The frequency of comorbidities at surgery was similar in the two groups. Five patients with difficult intubation were naive (4.3%) as compared with 5 SRL-pretreated patients (5.2%; P=1.0). ICAR registration did not show any significant change of intraoperative vital parameters in the two groups of patients as well as in the intraoperative utilization of drugs. Total duration of anesthesia and surgery were similar in the two groups. Four patients with an intraoperative adverse event were naive (3.5%) as compared with 4 SRL-pretreated patients (4.2%; P=1.00). Remission of disease occurred in 83 of 114 naive patients (72.8%) and in 57 of 93 SRL-pretreated patients (61.3%; P=0.11).Conclusions p id=Par4 SRL-pretreatment of patients with acromegaly had no significant impact on intraoperative anesthesiologic management. Despite a better Cormack-Lehane score in SRL-pretreated than in naive patients, the rate of difficult intubation was similar in both groups. SRL-pretreatment did not affect the rate of surgical remission or complications as well.